Diabetes treatment targeting abnormal stem cells

A diabetes and hematopoietic stem cell technology, applied in metabolic diseases, disease diagnosis, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc. Insufficient and other problems, to achieve the effect of good prognosis and low load

Pending Publication Date: 2022-07-29
BIOZIPCODE INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the details of the onset of both are unknown, it has to be said that the classification of type 1 and type 2 itself is not appropriate for identification based on etiology
In addition, various drugs are currently developed for the treatment of diabetes, but most of them are aimed at controlling blood sugar, and although they may be effective in preventing the development of diabetes, they may not be sufficient for curing diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diabetes treatment targeting abnormal stem cells
  • Diabetes treatment targeting abnormal stem cells
  • Diabetes treatment targeting abnormal stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0245] (Example 1: Identification of abnormal stem cells associated with diabetes)

[0246] To identify abnormal cells associated with diabetes, stem cells obtained from diabetes model mice were analyzed.

[0247] method

[0248] Acquisition of mouse and bone marrow cells

[0249] C57BL / 6J mice (wild type, CLEA, Japan, Osaka) were used in the experiments. Diabetes was induced by intravenous injection of streptozotocin (STZ) (150 mg / kg) (Nakalai Tesque, Kyoto) to create a type 2 diabetes model (STZ mice). Bone marrow cells were isolated from 8-week-old mice.

[0250] FACS

[0251] Mononuclear cells were isolated from whole bone marrow using Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).

[0252] To evaluate the expression of TNF-α and CD106, monocytes were stained with PE-Cy7-conjugated streptavidin antibody (BD Biosciences, San Jose, CA), Biotin Mouse Lineage Panel staining (BD Biosciences), APC-conjugated anti-c-kit antibody (BD Biosciences), APC-Cy...

Embodiment 2

[0258] (Example 2: Identification of abnormal stem cells associated with type 1 diabetes)

[0259] In the same manner as in Example 1, the stem cells obtained from the type 1 diabetes model mice were also characterized for abnormal cells related to diabetes.

[0260] method

[0261] Acquisition of mouse and bone marrow cells

[0262] For the test, ICR mice (CLEA, Osaka, Japan) and NOD mice (CLEA, Osaka, Japan) were used. Monocytes were isolated in the same manner as in Example 1.

[0263] As in Example 1, monocytes were stained for TNF-α, CD106, c-kit, Sca-1, and mouse lineage (Lineage), and FACS analysis was performed.

[0264] result

[0265] The proportion of KSL cells was reduced to about 25% in NOD mice compared to ICR mice ( Figure 4 ). The ratios of TNF-α-positive cells and CD106-expressing cells contained in the KSL cell population were significantly increased in NOD mice compared with ICR mice ( Figure 5 ).

[0266] TNF-α-positive cells and CD106-expressing ...

Embodiment 3

[0267] (Example 3: Cell stage of abnormal stem cells associated with diabetes)

[0268] Which stage of the abnormal stem cell is a hematopoietic stem cell is examined.

[0269] method

[0270]Side population cells (SP) of KSL cells were analyzed by FACS as reported by Goodell (cf. J Exp Med. 1996 Apr 1; ​​183(4): 1797-806; Nat Med. 1997 Dec; 3(12): 1337-45). Hoechest33342 pigment is cell permeable and binds to DNA, however, in hematopoietic stem cells, this pigment can be efficiently excreted outside the cell. Using this property, it was reported that the hematopoietic stem cell fraction was included in the unstained cells when UV light (350 nm) was used to excite bone marrow cells stained with the pigment, and when expanded in two optical filters, Hoechst blue and Hoechst red population (SP cells). Whole bone marrow cells were accurately stained at 37°C for 90 minutes using Hoechest 33342 (Sigma-Aldrich Japan K.K., Tokyo, Japan) as a pigment. To set the gating, Hoechest ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides treatment of diabetes mellitus targeting abnormal stem cells. In one embodiment, the invention provides treatment of diabetes and / or diseases, disorders and / or symptoms associated with diabetes targeting abnormal stem cells. In one embodiment, the present invention provides the diagnosis of diabetes and / or a disease, disorder and / or symptom associated with diabetes, or a risk thereof, metered by abnormal stem cells. In one embodiment, the abnormal stem cells of the invention are abnormal hematopoietic stem cells. In one embodiment, abnormal stem cells of the invention express CD106 at different levels than normal cells.

Description

technical field [0001] The present invention relates to the treatment of diabetes and / or related diseases targeting abnormal stem cells, and the diagnosis of diabetes and / or related diseases using abnormal stem cells as indicators. More particularly, the present invention relates to the treatment of diabetes and / or its associated diseases by inhibiting abnormal hematopoietic stem cells, and the diagnosis of diabetes and / or its associated diseases by detecting abnormal hematopoietic stem cells. Background technique [0002] Diabetes is generally classified into type 1 and type 2 (Non-Patent Document 1). However, since the details of the onset of both are unknown, it has to be said that the classification of type 1 and type 2 itself is not appropriate for identification on the basis of etiology. In addition, various drugs are currently developed for the treatment of diabetes, but most of them are aimed at controlling blood sugar. Although they may be effective in preventing t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K39/395A61P3/10A61P43/00C07K16/28C12N15/09C12Q1/04C12Q1/6827
CPCA61P3/10A61P43/00G01N33/5005C07K16/2836A61K2039/505A61K45/06G01N33/6893G01N2800/042
Inventor 小岛秀人寺岛智也樫美和子
Owner BIOZIPCODE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap